Capabilities of preoperative targeted therapy in treatment of bone metastases in renal cancer

Cover Page

Cite item

Full Text

Abstract

The study objective is to evaluate the effectiveness of preoperative targeted therapy, spectrum and rate of adverse events, as well as quality of life in patients with bone metastases of renal cell carcinoma.

Materials and methods. The study was conducted at the Research Institute of Oncology, Tomsk Medical Research Center between 2014 and 2018. The study included 34 patients with bone metastases of renal cell carcinoma who received preoperative targeted therapy with pazopanib for 8 weeks. All patients underwent surgical treatment of both the primary tumor and bone metastases.

Results and conclusion. It was shown that preoperative targeted therapy is characterized by a high rate of clinical response and satisfactory tolerability. In some cases, preoperative targeted therapy improves the conditions for surgical treatment of metastatic bone lesions, decreases intraoperative blood loss, decreases the volume and duration of surgical intervention, which, in turn, allows to preserve bigger range of motion in the affected bone segment and improve patients’ quality of life.

About the authors

Z. A. Yurmazov

Cancer Research Institute

Author for correspondence.
Email: Pzahar@sibmail.com
ORCID iD: 0000-0001-5629-8908

5 Kooperativny Pereulok, Tomsk 634009

Russian Federation

N. A. Lushnikova

Cancer Research Institute

Email: nadejdaland@gmail.com
ORCID iD: 0000-0003-3643-0101

5 Kooperativny Pereulok, Tomsk 634009

Russian Federation

L. V. Spirina

Cancer Research Institute;
Siberian State Medical University, Ministry of Health of Russia

Email: spirinalvl@mail.ru
ORCID iD: 0000-0002-5269-736X

5 Kooperativny Pereulok, Tomsk 634009, 

2 Moskovskiy Trakt, Tomsk 634050

Russian Federation

E. A. Usynin

Cancer Research Institute

Email: gusi@list.ru
ORCID iD: 0000-0001-7127-0188

5 Kooperativny Pereulok, Tomsk 634009

Russian Federation

E. M. Slonimskaya

Cancer Research Institute

Email: slonimskaya@yandex.ru
ORCID iD: 0000-0003-4382-5697

5 Kooperativny Pereulok, Tomsk 634009

Russian Federation

I. I. Anisenya

Cancer Research Institute

Email: anisenya@gmail.com
ORCID iD: 0000-0003-3882-4665

5 Kooperativny Pereulok, Tomsk 634009

Russian Federation

A. V. Bogoutdinova

Cancer Research Institute

Email: Bogoutdinova1972@gmail.com
ORCID iD: 0000-0001-6309-2000

5 Kooperativny Pereulok, Tomsk 634009

Russian Federation

References

  1. Heng D.Y., Xie W., Regan M.M. et al. External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population based study. Lancet Oncology 2013;14(2):141–8. doi: 10.1016/S1470-2045(12)70559-4.
  2. State of oncological care in Russia in 2017. Eds.: А.D. Kaprin, V.V. Starinskiy, G.V. Petrova. Moscow: MNIOI im. P.A. Gertsena – filial FGBU “NMIRTS radiologii” Minzdrava Rossii, 2018. 236 p. (In Russ.).
  3. Chandrasekar T., Klaassen Z., Goldberg H. et al. Metastatic renal cell carcinoma: Patterns and predictors of metastases – a contemporary population-based series. Urol Oncol 2017;35(11):661.e7–14. doi: 10.1016/j.urolonc.2017.06.060.
  4. Shirokorad V.I. , Kostritskii S.V., Zaborovskiy N.S. , Ptashnikov D.A. Combined treatment of metastatic renal cell carcinoma in spine. Onkourologiya = Cancer Urology 2017;13(2):43–8. (In Russ.).
  5. Kumar R., Crouthamel M.C., Rominger D.H. et al. Myelosuppression and kinase selectivity of multikinase angiogenesis inhibitors. Br J Cancer 2009;101(10): 1717–23. doi: 10.1038/sj.bjc.6605366.
  6. Alekseev B.Ya., Nyushko K.M., Kalpinsky A.S. Neoadjuvant targeted therapy in patients with renal cell carcinoma. Onkourologiya = Cancer Urology 2015;11(2):23–33. (In Russ.)].
  7. Subbiah V., Chuang H.H., Gambhire D., Kairemo K. Defining clinical response criteria and early response criteria for precision oncology: current state-of-the-art and future perspectives. Diagnostics (Basel) 2017;7(1):10. doi: 10.3390/diagnostics7010010.
  8. Hamaoka T., Madewell J.E., Podoloff D.A. et al. Bone imaging in metastatic breast cancer. J Clin Oncol 2004;22(14):2942–53. doi: 10.1200/JCO.2004.08.181.
  9. Costelloe C.M., Chuang H.H., Madewell J.E., Ueno N.T. Cancer response criteria and bone metastases: RECIST 1.1, MDA and PERCIST. J Cancer 2010;1:80–92. doi: 10.7150/jca.1.80.
  10. Kalra S., Verma J., Atkinson B.J. et al. Outcomes of patients with metastatic renal cell carcinoma and bone metastases in the targeted therapy era. Clin Genitourin Cancer 2017;15(3):363–70. DOI: https://doi.org/10.1016/j.clgc.2017.01.010.
  11. Chen S.C., Kuo P.L. Bone metastasis from renal cell carcinoma. Int J Mol Sci 2016;17(6). doi: 10.3390/ijms17060987.
  12. de Groot A.F., Appelman-Dijkstra N.M., van der Burg S.H., Kroep J.R. The antitumor effect of RANKL inhibition in malignant solid tumors – a systematic review. Cancer Treat Rev 2018;62:18–28. doi: 10.1016/j.ctrv.2017.10.010.
  13. Spirina L.V., Usynin E.A., Yurmazov Z.A. et al. Effect of targeted therapy with pazopanib on expression levels of transcription, growth factors and components of AKT/ m-TOR signaling pathway in patients with renal cell carcinoma. Asian Pac J Cancer Prev 2017;18(11):2977–83. doi: 10.22034/APJCP.2017.18.11.2977.
  14. Spirina L.V., Usynin E.A., Kondakova I.V. et al. Effect of targeted therapy on the content of transcription and growth fac tors, protein kinase TOR, and activity of intracellular proteases in patients with metastatic renal cell carcinoma. Bulleten eksperimentalnoy biologii i meditsiny = Bulletin of Experimental Biology and Medicine 2015;(12): 768–72. (In Russ.).
  15. Lucchesi M., Lanzetta G., Antonuzzo A. et al. Developing drugs in cancer-related bone pain. Crit Rev Oncol Hematol 2017;119:66–74. doi: 10.1016/j.critrevonc.2017.08.005.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c)


СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: серия ПИ № ФС 77-36986 от  21.07.2009.